Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, July 16, 2009
Wed, July 15, 2009 ChromoCure, Inc.: ChromoCure, Inc. Releases Interim Investor Guidance
RENO, NV--(Marketwire - July 15, 2009) - ChromoCure, Inc. (
Financial Reporting and Regular Disclosures
The Company believes regular disclosure sponsors an orderly and healthy market in its stock and attracts long-term investors. The Company is completing the process of activating the OTC Disclosure Service. Once complete, disclosures will be provided to the marketplace. To insure all market participants have equal and fair access to the company's disclosures, the Company will not release its information prior to OTC Disclosure Service activation. The Company believes it will complete this process within one week.
SEC "Fully reporting" status and regular SEC filings
The Company does not intend to register with the US Securities and Exchange Commission and thereby become "SEC fully reporting." In keeping with growing industry opinion and alongside an unprecedented and vast number of public companies voluntarily withdrawing their registrations, the Company does not believe registering with the SEC is in the best interests of either stockholders or the company. The prohibitive expenses and time demands are contrary to promoting shareholder equity or corporate growth. The Company believes the OTC Disclosure Service provides excellent investor communication and public transparency and is superior to the SEC's incomprehensible "EDGAR" filings. Should market conditions change, Management will revisit this decision.
Revenue Projections and Industry/Sector Analysis
The Company receives many inquiries regarding its technology, sales projections, and market strategy. The Company intends to disclose and make public several important components of its business plan and various "White Papers" on its technology. These disclosures will also contain various analyses of specific sectors of the cancer detection and diagnostic industry. Contained within these market surveys and analyses will be revenue estimates and projections. The Company will not release the disclosures and reports before OTC Disclosure Service activation. Upon release of these disclosures by way of Press Release and company web site, they will be concurrently filed on the OTC Disclosure Service to insure all investors have equal and timely access to current and accurate public information.
Current Stock Price and Market Valuation
Many stockholders have queried the Company's stock price. The Company has no control over the market price of its stock, but notes the following: The Company received its stock symbol on 9 July 2009. The Company's ticker has had four days of trading and audience within the financial community is momentarily small. A sparse investor population reflects itself in a stock's price and volume. Therefore, the Company's current share price may not be an accurate reflection of the company's ultimate value. While this point is obvious, we make note of it to inform stockholders of our efforts to increase our investor exposure. The Company believes a diverse shareholder base creates a more accurate reflection of a company's value. To attract quality long-term investors the Company works daily with the financial and investment community. The Company believes its market capitalization will steadily improve with each passing week as investor awareness expands.
The Company also believes results speak for themselves. As the company gains more worldwide media and scientific exposure for its proprietary technology, its vision, and its performance, the Company anticipates a growing audience of investors understanding the intrinsic value of ChromoCure.
Investors can anticipate updates on the following:
-- Complete retirement of prior long-term liabilities and addition of new technology assets. -- Further appointments of MDs and other industry professionals to the Company's Advisory and Business Development Boards. -- New additions to the Company's pathology and cancer lab revenue partners and new installations of the Company's Chromosomal Scanner. -- New technology and equipment vendor agreements for national joint venture marketing and sales. -- Full business plan information and regular technology briefings on the company's cancer detection technologies.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic common to all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.
The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's website version of this press release contains various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
